Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021
By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.
- By systematically identifying urgent infections with unmet needs, Appili\xe2\x80\x99s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.
- As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan\xc2\xae / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19.
- Led by a proven management team, Appili is at the epicenter of the global fight against infection.
- For more information, visit www.AppiliTherapeutics.com .\nBloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies.